top of page
TT3A logo.png

Trans-catheter treatment of ascending aorta aneurysms (TT3A)

 

Start
TT3A S.r.l. is developing the first on-label structural heart medical device to treat patients with ascending aorta aneurisms. Current surgical treatments of this pathology result in up to an 80% mortality rate. Therefore, our primary objective is to reduce mortality, and hospitalization time.  
 
Complete website coming soon. 
External venture of

 

Contact Antonello Fazio (CEO): af@tt3a.com

SQUADRA-logo.png
About & Subscribe
bottom of page